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Abstract
Due to the success of the Global Programme to Eliminate Lymphatic Filariasis (GPELF)
many countries have either eliminated the disease as a public health problem or are sched-
uled to achieve this elimination status in the coming years. The World Health Organization
(WHO) recommend that the Transmission Assessment Survey (TAS) is used routinely for
post-mass drug administration (MDA) surveillance but it is considered to lack sensitivity in
low prevalence settings and not be suitable for post-validation surveillance. Currently there
is limited evidence to support programme managers on the design of appropriate alternative
strategies to TAS that can be used for post-validation surveillance, as recommended by the
WHO. We searched for human and mosquito LF surveillance studies conducted between
January 2000 and December 2018 in countries which had either completed MDA or had
been validated as having eliminated LF. Article screening and selection were independently
conducted. 44 papers met the eligibility criteria, summarising evidence from 22 countries
and comprising 83 methodologically distinct surveillance studies. No standardised approach
was reported. The most common study type was community-based human testing (n = 42,
47.2%), followed by mosquito xenomonitoring (n = 23, 25.8%) and alternative (non-TAS)
forms of school-based human testing (n = 19, 21.3%). Most studies were cross-sectional (n
= 61, 73.5%) and used non-random sampling methods. 11 different human diagnostic tests
were described. Results suggest that sensitivity of LF surveillance can be increased by
incorporating newer human diagnostic tests (including antibody tests) and the use of mos-
quito xenomonitoring may be able to help identify and target areas of active transmission.
Alternative sampling methods including the addition of adults to routine surveillance meth-
ods and consideration of community-based sampling could also increase sensitivity. The
evidence base to support post-validation surveillance remains limited. Further research is
needed on the diagnostic performance and cost-effectiveness of new diagnostic tests and
methodologies to guide policy decisions and must be conducted in a range of countries. Evi-
dence on how to integrate surveillance within other routine healthcare processes is also
important to support the ongoing sustainability of LF surveillance.
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Author summary
Lymphatic filariasis (LF) is a mosquito-borne disease, which can result in complications
including swelling affecting the limbs (lymphoedema) or scrotum (hydrocele). LF can be
eliminated by mass drug administration (MDA) which involves whole communities tak-
ing drug treatment at regular intervals. After MDA programmes, country programmes
conduct the Transmission Assessment Survey (TAS), which tests school children for LF.
It is important to continue testing for LF after elimination because there can be a 10-year
period between becoming infected and developing symptoms, but it is thought that the
use of TAS in such settings is likely to be too expensive and also not sensitive enough to
detect low-level infections. Our study assesses the results from 44 studies in areas of low
LF prevalence that have investigated methods of surveillance for LF which differ from the
standardised TAS approach. These include both human and mosquito studies. Results
show that there is currently no standardised approach to testing, but that surveillance can
be made more sensitive through the use of new diagnostic tests, such as antibody testing,
and also by targeting higher risk populations. However, further research is needed to
understand whether these approaches work in a range of settings and whether they are
affordable on the ground.
Introduction
Lymphatic filariasis (LF) is a mosquito-borne parasitic infection which is caused by three spe-
cies of filarial worms: Wuchereria bancrofti, Brugia malayi and Brugia timori[1, 2]. It can dam-
age the human lymphatic system, resulting in disabling complications including
lymphoedema and hydrocele[1]. An estimated 886 million people live in areas at risk of LF
infection and 36 million people are currently suffering from LF-related complications[2].
The Global Programme to Eliminate LF (GPELF) was established in 2000 with the intention
of eliminating LF as a public health problem[3]. This has involved actions to interrupt trans-
mission, through the systematic delivery of mass drug administration (MDA) at a population
level, and to ensure that cases of morbidity linked to LF receive appropriate treatment[4].
Since 2010, demonstrating interruption of transmission has required three successful
Transmission Assessment Surveys (TAS). These are school-based surveys which use rapid
antigen tests (e.g. BinaxNOW) to sample a population of 6-7-year-old children at least 6
months after the final MDA[4, 5]. Successful delivery of these TASs allows a country to be vali-
dated as having eliminated LF as a public health problem.
By the end of 2018, 14 countries had been validated as having eliminated LF, with a further
59 requiring ongoing interventions and surveillance[2]. In the coming decade, many of these
countries are expected to be validated as having achieved elimination status. This work is sup-
ported by the continued funding commitment from international donors and new drug regi-
mens such as triple therapy which could be scaled up in challenging areas, including India
which has the largest burden of disease[1, 6].
Following validation of elimination of LF as a public health problem, the WHO recommend
that countries continue surveillance for LF to detect any possible recrudescence of infection
but there are no clear recommendations on specific surveillance methods and thresholds to be
used[4, 6]. It is acknowledged that the TAS methodology is resource-intensive and may also
lack sensitivity in low-prevalence settings[5, 7]. Consequently, there is increasing interest in
the appropriateness and effectiveness of alternative methods of LF surveillance, and whether
these can be integrated within health systems in post-validation settings.
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This review focuses on alternative (non-TAS) LF surveillance studies conducted in low-
prevalence settings since 2000, including both human and mosquito studies. This cut-off rep-
resents the establishment of GPELF and the introduction of a more standardised approach to
LF surveillance and the emergence of newer diagnostic tests. It aims to describe these studies
in relation to factors including diagnostic tests, sampling methods and reported results, and to
compare results with concurrent TAS outcomes where possible, in order to make recommen-
dations to programme managers and highlight areas requiring further research.
Methods
Protocol and registration
This review was conducted and reported according to Preferred Reporting Items for System-
atic Reviews and Meta-analyses Statement (PRISMA) guidelines (S1 File).
Search strategy
The following databases were searched for papers published from 2000 to November 2018:
PubMed, Scopus and the Cochrane Database of Systematic Reviews. A combination of MeSH
terms and text words were used to describe concepts relating to both LF and surveillance (S2
File). Any additional papers found to be relevant during this process were included.
Inclusion criteria
Studies were included in the systematic review if they (1) were a primary research study inves-
tigating methods of population-based LF surveillance other than routine TAS surveys; (2)
included surveillance methods pertaining to either humans (reservoir) and/or mosquitoes
(vector); and (3) were conducted in a low prevalence setting, either post-MDA or post-valida-
tion. The review was limited to English-language publications with full-text availability con-
ducted after 2000, following the establishment of the GPELF. Studies describing diagnostic test
studies were not included if their design did not include population-level sampling.
Study selection and data extraction
A two-stage process was followed for data selection. Firstly, titles and abstracts of all eligible stud-
ies were independently reviewed (co-authors NR and XBR). Any article deemed ‘potentially’ rele-
vant then underwent independent full-text review (NR and XBR). Discrepant ratings for any
papers at stage two were discussed until consensus was reached. A standardised data extraction
form was developed, piloted and refined. Where papers reported on more than one study design,
these were extracted separately. NR extracted from all the papers and XBR extracted from a sam-
ple of 10% of the total. No significant discrepancies were identified during this process.
Extraction focused on the core themes identified during scoping work: (1) location (WHO
Region and country, predominant mosquito type); (2) programme context (number of MDA
rounds, date of last MDA and elimination status; (3) study design; (4) sampling strategy
(including sample size and sampling methods); (5) diagnostic tests used; (6) outcomes of sur-
veillance activity, including comparison with TAS results where applicable; and (7) integration
of surveillance with other disease programmes.
Risk of bias assessment
Risk of bias was assessed using a modified version of the Crowe and GATE validated appraisal
tools. Scores of 0–2 were assigned for all studies based on study design (not stated, cross-sec-
tional, longitudinal). Human sampling studies were further assessed in relation to sample size
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terciles (0-760/761-2,464/>2,464), method of sampling participants (not stated/non-random/
random) and study population (not stated/children or adults/children and adults). Mosquito
sampling studies also assigned scores according to sample size terciles (0–4,679/4,680–10,871/
>10,871), catch-site sampling (not stated, non-random, random) and method of analysis (not
stated/dissection/PCR analysis). It was decided not to include location sampling in the assess-
ment since it may be preferable to use non-random methods in some scenarios (e.g. conduct-
ing surveillance activities in response to a suspected hotspot). Total risk of bias scores (marked
out of 8) were calculated for each study and are presented in Tables 2 and 4. A full breakdown
of scores for each study is listed in S1 Table.
Data synthesis and analysis
Details of publication details, programme context and study design are presented for all studies
combined. This is followed by data on sampling strategy, diagnostic test usage and outcomes,
split for human and mosquito surveillance studies separately. The impact of age and gender on
diagnostic test performance in humans is explored. Analysis then included: (1) comparison
between human and mosquito surveillance studies; (2) comparison with TAS results, where
applicable; and (3) evidence of integration of surveillance methods within health systems. The
analysis aims to determine factors which can increase the sensitivity (defined as the proportion
of true positive cases identified by a diagnostic test) in low prevalence settings.
Results
Selected studies
Fig 1 highlights the PRISMA steps of identification, screening, eligibility and inclusion of
papers. A total of 1,378 papers were identified from the initial search, once duplicates had been
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pntd.0008289.g001
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excluded. Of these, 71 were considered potentially relevant following title/abstract screening
by two independent reviewers. 57 of these were labelled potentially relevant by at least one
reviewer following full-text screening. When discrepant results were reviewed, this total
reduced to 40 papers which then proceeded to data extraction. An additional four papers were
identified during the peer review process. The 44 papers which met eligibility criteria com-
prised of 83 methodologically distinct study designs (Table 1). These studies are henceforth
considered separately except for one paper which pooled results of school and community
surveys.
A significant degree of heterogeneity was identified in the included studies. This included
variation in study design, baseline endemicity, population sampled, use of diagnostic tests and
reporting metrics. It was agreed that this variation precluded formal meta-analysis and instead
required a narrative review structured according to the core themes identified.
Publication details. 26 papers (59.1%) were published between 2015–2019, 15 (34.1%)
were published between 2010–2014 and 3 (6.8%) between 2005–2009. 23 (52.3%) papers
reported on human surveillance only, 9 (20.5%) on mosquito surveillance only and 12 (27.2%)
reported on both human and mosquito surveillance together.
Location (WHO Region and country). Papers reported data from 22 countries in total;
21 (41.1%) came from the Western Pacific Region, 13 (25.5%) from the African Region, 12
(23.5%) from the South East Asian Region, 4 (7.8%) from the Eastern Mediterranean Region
and 1 (2.0%) from the Region of the Americas. Fig 2 shows the geographical distribution of
countries included in the review.
Programme context. 72 (86.7%) studies reported data from countries which had com-
pleted MDA but had not yet completed TAS. 11 studies (13.3%) were from countries validated
as having eliminated LF, of which two studies described surveillance following successful com-
pletion of TAS. 36 (70.6%) studies reported on previous MDA activity, for which the median
number of MDA rounds prior to surveillance was 5 (range 3 to 13).
Predominant mosquito type. Studies were conducted in areas with a range of different
mosquito vector genera, most commonly Anopheles sp (n = 15, 29.4%) from the African and
Table 1. Characteristics of included studies.
Description No. of studies (%)
Study start date
2000–2004 6 (7.2%)
2005–2009 31 (37.3%)
2010–2014 19 (22.9%)
2015–2019 16 (19.3%)
Not stated 11 (13.3%)
Study type
Cross-sectional 61 (73.5%)
Longitudinal 22 (26.5%)
Surveillance method
Community survey 42 (47.2%)
School survey 19 (21.3%)
Laboratory surveillance 2 (2.2%)
Health centre surveillance 1 (1.1%)
Active surveillance 1 (1.1%)
Occupational surveillance 1 (1.1%)
Xenomonitoring survey 23 (25.8%)
https://doi.org/10.1371/journal.pntd.0008289.t001
PLOS NEGLECTED TROPICAL DISEASES Alternative surveillance approaches for lymphatic filariasis in low prevalence settings
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008289 May 12, 2020 5 / 22
Western Pacific Regions, Culex sp (n = 13, 25.5%) from studies in the South East Asian and
Eastern Mediterranean Regions, and Aedes sp (n = 12, 23.5%) from the Western Pacific
Region. A further 12 studies (23.5%) were conducted in settings with more than one vector for
LF according to the WHO Practical Entomology manual[8].
Study design. 61 studies (73.5%) were cross-sectional in design and 22 (26.5%) were lon-
gitudinal studies. The most common study designs were community surveys (n = 42; 47.2%),
xenomonitoring surveys (n = 23; 25.8%) and school surveys (n = 13; 14.6%).
Human surveillance studies
Table 2 summarises the characteristics of the 35 papers which reported data on human surveil-
lance for lymphatic filariasis, comprising 60 distinct studies. Full results from these studies can
be found in S2 Table.
Sample size. The median sample size was 1,472 (range = 40 to 35,582; interquartile
range = 596–3,207). The majority of studies (n = 36; 60.0%) included both children and adults
in their study design. 15 studies (25.0%) focused on children only and five (8.3%) on adults
only. In total, the studies reported data on 208,568 participants.
Sampling methods. Where stated (n = 42), the most common approach to selecting a
sampling location involved non-random methods, such as purposive or convenience sampling
(n = 30, 71.4%). In most cases surveillance was conducted in response to identification of a
hotspot of infection. Other methods involved using random sampling methods (n = 7, 17.5%)
while four studies described national surveillance studies [10, 11, 31]. Participants were then
sampled using either non-random methods (n = 34, 69.3%) or random methods (n = 15,
30.6%).
Diagnostic tests. Included studies described results using 12 different diagnostic tests. 58
studies involved blood samples of which the majority were finger prick samples. The most
common tests were microscopy for microfilaraemia (MF) (n = 38; 63.3%); BinaxNOW
(n = 36; 60.0%); Bm14 Ab (n = 20; 33.3%), Og4C3 Ag (n = 17; 28.3%), Wb123 Ab (n = 9;
15.0%) and Wb PCR (8, 13.3%). Table 3 compares results where the same diagnostic test was
Fig 2. Map of countries reporting data. For highly populated countries (e.g. Nigeria and India) where mapping was not nationally representative, the specific area/
region being sampled is highlighted. These data were extracted from the Geoconnect website (https://www.geoconnect.org/).
https://doi.org/10.1371/journal.pntd.0008289.g002
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Table 2. Human surveillance study characteristics.
Country
(last MDA)1
Reference
(Quality score)
Study date Context Study design Age criteria Total sample
size
Tests performed
American
Samoa (2007)
Mladonicky et al.
2009 [9] (4/8)
2006 Post-MDA Cross-sectional
community survey
�5 years 579 BinaxNOW, MF, Bm14 Ab
Coutts et al. 2017
[10] (6/8)
2007 Post-MDA Cross-sectional
community survey
�2 years 1,881 BinaxNOW
Lau et al. 2014 [11]
(5/8)
2010 Post-MDA Cross-sectional
community survey
�18 years 807 Og4cC3 Ag>128 units, Og4cC3
Ag>32 units, Wb123 Ab, Bm14
Ab
Lau et al. 2017a [12]
(4/8)
2014 Post-MDA Cross-sectional
occupational survey
�15 years 602 BinaxNOW, Og4C3 Ag, Bm14 Ab,
Wb123 Ab
Lau et al. 2017b [12]
(4/8)
2014 Post-MDA Cross-sectional
community survey
�2 years 476 BinaxNOW, Og4C3 Ag, Bm14 Ab,
Wb123 Ab
Lau et al. 2017c [12]
(4/8)
2014 Post-MDA Cross-sectional school
survey
7–13 years 283 BinaxNOW
Won et al. 2018 [13]
(5/8)
2015 Post-MDA Longitudinal school
survey
5–10 years 1,134(TAS
1)
864(TAS 2)
BinaxNOW, Wb123 Ab, Bm14
Ab, Bm33 Ab
Sheel et al. 2018 [14]
(7/8)
2016 Post-MDA Cross-sectional
community survey
�8 years 2,507 MF, FTS (filarial test strips)
China Huang et al. 2016a
[15] (2/8)
2002 Post-
validation
Cross-sectional school
survey
Children 542 Chinese filariasis IgG4 ELISA kit,
MF
Huang et al. 2016b
[15] (1/8)
2003 Post-
validation
Cross-sectional
community survey
Not stated 436 Chinese filariasis IgG4 ELISA kit
Huang et al. 2016c
[15] (3/8)
2004 Post-
validation
Cross-sectional
community survey
Not stated 5,787 Chinese filariasis IgG4 ELISA kit
Huang et al. 2016d
[15] (4/8)
2002 and
2004
Post-
validation
Cross-sectional
community survey
Children and
adults
762 Chinese filariasis IgG4 ELISA kit,
MF
Huang et al. 2016e
[15] (2/8)
2002–2008 Post-
validation
Longitudinal community
survey
Not stated 218 Chinese filariasis IgG4 ELISA kit
Itoh et al. 2007 [16]
(4/8)
2004 Post-
validation
Cross-sectional school
survey
6 to 10 years
(Yongjia)
5–15 years
(Gaoan)
2,411
(Yongjia)
7,998
(Gaoan)
IgG4 ELISA (urinary)
Egypt
(2005)
Moustafa et al. 2014a
[17] (4/8)
2012 Post-MDA Cross-sectional school
survey
6–7 years 1,321 BinaxNOW, Bm14Ab
Moustafa et al.
2014b [17] (3/8)
2012 Post-MDA Cross-sectional
community survey
16–60 years 75 BinaxNOW
Ramzy et al. 2006a
[18] (7/8)
Not stated Post-MDA Longitudinal community
survey
�4 years 1,064 (Giza)
744
(Qalubiya)
BinaxNOW, MF
Ramzy et al. 2006b
[18] (4/8)
Not stated Post-MDA Longitudinal school
survey
7 and 11 years 1,653 BinaxNOW, Bm14 Ab
French
Polynesia
Gass et al. 2011a [19]
(5/8)
2007–2008 Post-MDA Cross-sectional school
and community survey
3–80 years 1,383 Bm14 Ab, PanLF, Urine SXP, ICT,
Og4C3 Ag, MF, PCR
Gambia Won et al. 2018 [20]
(6/8)
2015 Post-
validation
Cross-sectional
community survey
�1 year 2,612 Wb 123 Ab ELISA, Bm14 Ab
ELISA
Ghana Gass et al. 2011b
[19] (5/8)
2007–2008 Post-MDA Cross-sectional school
and community survey
3–80 years 1,466 Bm14 Ab, ICT, Og4C3 Ag, MF,
PCR
Owusu et al. 2015a
[21] (4/8)
2008 Post-MDA Cross-sectional school
survey
6–7 and 10–11
years
308 BinaxNOW, Og4C3 Ag, Bm14 Ab,
Wb123 Ab
Owusu et al. 2015b
[21] (5/8)
2008 Post-MDA Cross-sectional
community survey
3–80 years 653 BinaxNOW, MF, Og4C3 Ag,
Bm14 Ab, Wb123 Ab
Haiti Gass et al. 2011c [19]
(5/8)
2007–2008 Post-MDA Cross-sectional survey 3–80 years 1,322 Bm14 Ab, PanLF, Urine SXP, ICT,
Og4C3 Ag, MF, PCR
(Continued)
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Table 2. (Continued)
Country
(last MDA)1
Reference
(Quality score)
Study date Context Study design Age criteria Total sample
size
Tests performed
India
(2011)
(2007)
(2004)
Ramaiah et al. 2013
[22] (6/8)
2005–2008 Post-MDA Longitudinal Adults and
children
Approx. 700 MF, BinaxNOW
Swaminathan et al.
2012 [23] (6/8)
2015–2017 Post-MDA Cross-sectional
community survey
�2 years 35,582 MF, Og4C3 Ag
Mehta et al. 2018
[24] (3/8)
Study year
not reported
Post-MDA Cross-sectional
community survey
�5 years 290 BinaxNOW, MF
Madagascar
(2016)
Garchitorena et al.
2018 [25] (5/8)
2016 Post-MDA Cross-sectional
community survey
�5 years 545 FTS
Mali
(2008)
Coulibaly et al. 2015
[26] (5/8)
2007 Post-MDA Longitudinal community
survey
�2 years 760 BinaxNOW, MF
Coulibaly et al.
2016a [27] (6/8)
2009–2013 Post-MDA Longitudinal community
survey
6–7 years 3,457 BinaxNOW, MF (if BinaxNOW
positive), Wb PCR, Wb123 Ab,
Og4C3 Ag
Coulibaly et al.
2016b [27] (5/8)
2009–2013 Post-MDA Longitudinal community
survey
�8 years 1,184 BinaxNOW, MF (if BinaxNOW
positive), Wb PCR, Wb123 Ab,
Og4C3 Ag
Nigeria
(2009)
Richards et al. 2011
[28] (6/8)
2009 Post-MDA Longitudinal community
survey
�2 years 1,720 BinaxNOW, MF
Papua New
Guinea
Mitja et al. 2011 [29]
(6/8)
2011 Post-MDA Longitudinal community
survey
Not stated 6,263 BinaxNOW
Samoa
(2008)
Joseph et al. 2011A
[30]2 (7/8)
2007 Post-MDA Cross-sectional
community survey
Any age 6,648 BinaxNOW, MF (if BinaxNOW
+ve), BM14 Ab (children aged
5–10 years only)
Joseph et al. 2011Ba
[31]2 (7/8)
2008 Post-MDA Cross-sectional
community survey
�2 years 2,474 BinaxNOW, MF, BM14 Ab
Solomon
Islands
(N/A)
Harrington et al.
2013 [32] (4/8)
2011 Post-
validation
Cross-sectional
community survey
Adults and
children
307 Og4C3Ag, MF (if ICT positive/
borderline plus 10% of negative
screens)
Sri Lanka
(2015)
Rao et al. 2016 [33]
(7/8)
2013 Post-MDA Cross-sectional
community survey
2–70 years 12,977 MF
Gass et al. 2011d
[19] (5/8)
2007–2008 Post-MDA Cross-sectional school
and community survey
3–80 years 1,477 PanLF, ICT, Og4C3 Ag, MF, PCR
Chandrasena et al.
2016a [34] (6/8)
2009–2015 Post-MDA Longitudinal community
survey
4–80 years 2,461 MF
Chandrasena et al.
2016b [34] (2/8)
2015 Post-MDA Cross-sectional
community survey
7–12 years 250 Brugia Rapid
Rahman et al. 2018a
[35] (4/8)
Not stated Post-TAS Cross-sectional
community survey
5–84 years 630 MF, FTS
Rahman et al. 2018b
[35] (4/8)
Not stated Post-TAS Cross-sectional school
survey
5–13 years 2,301 IgG4 ELISA (urinary)
Rao et al. 2014a [36]
(7/8)
2011–2013 Post-MDA Cross-sectional
community survey
�10 years 7,156 BinaxNOW, MF
Rao et al. 2014b [36]
(5/8)
Not stated Post-MDA Cross-sectional school
survey
Grade 1 and 2 17,000 BinaxNOW, BM14 Ab
Rao et al. 2017a [37]
(4/8)
2015–2017 Post-MDA Cross-sectional school
survey
6–8 years 2,227 BinaxNOW, MF if BinaxNOW
+ve, BM14 Ab
Rao et al. 2017b [37]
(7/8)
2015–2017 Post-MDA Cross-sectional
community survey
�10 years 3,123 BinaxNOW, MF if BinaxNOW
+ve
Rao et al. 2018a [38]
(3/8)
2015 Post-MDA Cross-sectional school
survey
First and second
grade children
401 BinaxNOW, BM14 Ab, MF
Rao et al. 2018b [38]
(5/8)
2015 Post-MDA Cross-sectional
community survey
10–70 years 528 BinaxNOW, MF
Rao et al. 2018c [38]
(7/8)
2015 Post-MDA Cross-sectional
community survey
�2 years 16,927 MF
(Continued)
PLOS NEGLECTED TROPICAL DISEASES Alternative surveillance approaches for lymphatic filariasis in low prevalence settings
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008289 May 12, 2020 8 / 22
used in the same population, allowing direct comparison of prevalence values within each
study. Compared to Binax Now or Alere ICT (the most commonly used tests at the time of
most of these surveys) as the index test, Table 3 shows that antibody tests produce a higher
proportion of positive results. Bm14Ab and Wb123Ab values are, on average, 5.1 and 6.7 times
higher respectively than the corresponding BinaxNOW values, based on the median value of
this ratio across the selected studies. Og4C3Ag values are similar to BinaxNOW values in stud-
ies where both are used (median ratio = 0.95, range 0.2–1.6).
Impact of age. Age-specific prevalence was extracted for twelve different LF diagnostic
tests from studies which reported data allowing 10-year age bands to be calculated (Fig 3). A
similar pattern is seen for each test, with rates generally increasing through childhood and ado-
lescence before stabilising during adulthood and occasionally falling in older age.
Impact of gender. Reported prevalence of LF tests are also known to generally be higher
among men in comparison to women (Fig 4).
Mosquito surveillance studies
Table 4 summarises the characteristics of the 23 papers which reported data on mosquito sur-
veillance for LF. Full results from these studies can be found in S3 Table.
Sample size. The median number of mosquitoes collected was 7,860 per study (range
115–69,680, interquartile range 4,383–18,865).
Sampling methods. Similar to human surveillance studies, location sampling typically
used non-random methods, following identification of a hotspot area by other methods. The
Table 2. (Continued)
Country
(last MDA)1
Reference
(Quality score)
Study date Context Study design Age criteria Total sample
size
Tests performed
Tanzania
(2014)
Gass et al. 2011e [19]
(5/8)
2007–2008 Post-MDA Cross-sectional school
and community survey
3–80 years 1,384 Urine SXP, ICT, Og4C3 Ag, PCR
Jones et al. 2018 [29,
39] (6/8)
2015 Post-MDA Cross-sectional
community survey
10–79 years 854 BinaxNOW
Togo
(2009)
Budge et al. 2014a
[40] (6/8)
2006–2007 Post-MDA Longitudinal laboratory
surveillance study
Adults 6,509 MF
Budge et al. 2014b
[40] (5/8)
2006–2007 Post-MDA Cross-sectional
community survey
Adults 7,800 BinaxNOW
Budge et al. 2014c
[40] (6/8)
2010–2011 Post-MDA Longitudinal health
facility surveillance study
Adults 2,880 Og4C3 Ag, MF (if Ag +ve)
Mathieu et al. 2011
[41] (5/8)
2006–2007 Post-MDA Longitudinal laboratory
surveillance study
Not stated 8,050 MF
Dorkenoo et al.
2018A [42] (4/8)
2010–2015 Post-MDA Cross-sectional active
surveillance of positive
cases
Children and
adults
40 MF, Og4c3 Ag, FTS
Tonga
(2005)
Joseph et al. 2011Bb
[31] (4/8)
2007 Post-MDA Cross-sectional school
survey
5–6 years 797 BinaxNOW, MF (if ICT +ve),
BM14 Ab
Tuvalu Gass et al. 2011f [19]
(5/8)
2007–2008 Post-MDA Cross-sectional school
and community survey
3–80 years 1,481 PanLF, Urine SXP, ICT, Og4C3
Ag, MF, PCR
Vanuatu
(2005)
Joseph et al. 2011Bc
[31] (5/8)
2007 Post-MDA Cross-sectional school
survey
5–6 years 3,840 BinaxNOW, MF (if ICT +ve),
BM14 Ab
Allen at al. 2017 [43]
(7/8)
2005–2006 Post-MDA Cross-sectional
community survey
�1 year 7,657 BinaxNOW, MF (if ICT +ve
1 According to country or region-level, where stated in papers
2 MDA in Samoa was subsequently re-started, commencing in 2008
https://doi.org/10.1371/journal.pntd.0008289.t002
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majority of studies then described various methods for taking a random sample of households
from which to sample mosquitoes, either indoors or outdoors. The most common mosquito
sampling method was the gravid trap (n = 9; 39.1%) followed by various baited traps (n = 6;
Table 3. Comparison of diagnostic test results when used for human surveillance in LF, using BinaxNOW as the index test.
Country Reference Diagnostic test prevalence
BinaxNOW
(Index test)
Bm14 Ab Og4C3 Ag1 Wb123 Ab
Prevalence
(population tested)
Ratio cf.
index test
Prevalence
(population tested)
Ratio cf.
index test
Prevalence
(population tested)
Ratio cf.
index test
American
Samoa
Lau et al. 2017a
[12]
1.3% (n = 602) 11.7% (n = 598) 9.0 1.2% (n = 598) 0.9 10.9% (n = 598) 8.4
Lau et al. 2017b2
[12]
8.2% (n = 151) 25.2% (n = 150) 2.4 11.2% (n = 150) 1.4 32.5% (n = 150) 4.0
Mladonicky et al.
20092 [9]
4.2% (n = 569) 14.1% (n = 538) 3.4 - - - -
Won et al. 2018
[13]
0.2% (n = 937) 6.8% (n = 1,112) 34.0 - - 1.0% (n = 1,112) 5.0
Won et al. 2018
[13]
0.1% (n = 768) 3.0% (n = 836) 30.0 - - 3.6% (n = 836) 36.0
Egypt Moustafa et al.
2014 [17]
0.0%
(n = 1,321)
2.2% (n = 1,321) N/A - - - -
French
Polynesia
Gass et al. (2011)
[19]
9.0%
(n = 1,359)
46.0% (n = 1,329) 5.1 6.4% (1,355) 0.7 - -
Ghana Gass et al. (2011) 6.7%
(n = 1,372)
9.9% (n = 1,159) 1.5 8.9% (n = 1,355) 1.3 - -
Ghana Owusu et al. 2015a
[21]
1.6% (n = 308) 4.9% (n = 308) 3.1 1.0% (n = 308) 0.6 - -
Owusu et al. 2015a
[21]
7.8% (n = 653) 12.9% (n = 653) 1.7 12.2% (n = 653) 1.6 - -
Haiti Gass et al. (2011)
[19]
21.2%
(n = 1,266)
53.1% (n = 1,214) 2.5 18.8% (n = 1,179) 0.9 - -
Samoa Joseph et al. 20112
[31]
7.7% (2,026) 62.7% (n = 2,026) 8.1 - - - -
Sri Lanka Gass et al. (2011)
[19]
3.0%
(n = 1,449)
- - 0.5% (n = 1,432) 0.2 - -
Rao et al. 20172
[37]
0.3%
(n = 1,893)
1.9% (n = 2,126) 6.3 - - - -
Rao et al. 20142
[36]
0.2%
(n = 2,561)
10.6% (n = 2,110) 53 - - - -
Rao et al. 2014b
[36]
0.05%
(n = 6,198)
2.2% (n = 6,198) 44 - - - -
Rao et al. 2018a
[38]
1.2% (n = 401) 5.7% (n = 387) 4.75 - - - -
Tanzania Gass et al. (2011)
[19]
8.1%
(n = 1,316)
- - 8.2% (n = 1,126) 1.0 - -
Tonga Joseph et al.
2011Bb [31]
0% (n = 797) 6.3% (n = 797) N/A - - - -
Tuvalu Gass et al. (2011)
[19]
5.0%
(n = 1,455)
- 4.9% (1,333) 1.0 - -
Vanuatu Joseph et al.
2011Bc [31]
0% (n = 3,840) 6.0% (n = 3,840) N/A - - - -
1 A threshold value of >32 units was selected for Og4C3 Ag when multiple values were presented.
2 Weighted average of component studies
3 Standard TAS with the addition of antibody testing
https://doi.org/10.1371/journal.pntd.0008289.t003
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26.1%), human landing collection (n = 5; 21.7%) and pyrethrum space spray catches (n = 4;
17.4%). The variation was partly due to the different species of mosquito being sampled.
Table 4. Mosquito diagnostic study characteristics
Country (last
known MDA)1
Main vector Reference (Quality
score)
Study
date
Context Study design Catch method Sample size Analysis
method
American Samoa
(2007)
Aedes spp. Schmaedick et al.
2014 [44] (6/8)
2011 Post-MDA Cross-sectional
survey
BG-Sentinel traps 21,861
mosquitoes
PCR analysis
Bangladesh Culex spp. Irish et al. 2018 [45]
(6/8)
2016 Post-MDA Cross-sectional
survey
CDC gravid traps 5,926
mosquitoes
PCR analysis
Egypt (2013) Culex spp. Ramzy et al. 2006 [18]
(7/8)
Not
stated
Post-MDA Longitudinal
survey
Aspiration of indoor resting
mosquitoes
8,531
mosquitoes
PCR analysis
Abdel-Shafi et al. 2016
[46] (5/8)
2014–
15
Post-MDA Cross-sectional
survey
Light traps Not stated PCR analysis
Moustafa et al. 2017
[47] (4/8)
2014 Post-MDA Cross-sectional
survey
Gravid traps 7,970
mosquitoes
PCR analysis
Ghana Multiple Owusu et al. 2015a
[21] (5/8)
2008 Post-MDA Cross-sectional
survey
Pyrethrum knockdown method 401
mosquitoes
PCR analysis
Owusu et al. 2015b
[21] (5/8)
2008 Post-MDA Cross-sectional
survey
Gravid trap 4,099
mosquitoes
PCR analysis
India (2011/
2007/ 2004)
Multiple Ramaiah et al. 2013
[22] (4/8)
2005–
2010
Post-MDA Longitudinal
survey
Aspiration of indoor resting
mosquitoes
10,842
mosquitoes
Dissection
Subramanaian et al.
2017 [48] (8/8)
2012 Post-MDA Longitudinal
survey
CDC gravid traps 41,294
mosquitoes
PCR analysis
Mehta et al. 2018 [24]
(3/8)
Not
stated
Post-MDA Cross-sectional
survey
Gravid trap 2,429
mosquitoes
Dissection
Malaysia Multiple Beng et al. 2016 [49]
(3/8)
Not
stated
Post-MDA Cross-sectional
survey
Bare leg catch and CDC light
trap
4,378
mosquitoes
PCR analysis
Mali (2008) Anopheles
spp.
Coulibaly et al. 2015
[26] (4/8)
2007 Post-MDA Longitudinal
survey
Human landing catch 4,680
mosquitoes
Dissection
Coulibaly et al. 2016a
[27] (5/8)
2009–
2013
Post-MDA Longitudinal
survey
Human landing catch 14,424
mosquitoes
Dissection
Coulibaly et al. 2016b
[27] (6/8)
2012 Post-MDA Longitudinal
survey
Pyrethrum spray catch 115
mosquitoes
PCR analysis
Nigeria (2009) Anopheles
spp.
Richards et al. 2011
[28] (4/8)
2009 Post-MDA Longitudinal
survey
Pyrethrum knockdown method 4,398
mosquitoes
Dissection
Papua New
Guinea (1998)
Anopheles
spp.
Reimer et al. 2013
[50] (5/8)
2007–
2008
Post-MDA Longitudinal
survey
Human landing catch 20,345
mosquitoes
PCR analysis
South Korea
(multiple)
Multiple Cho et al. 2012 [51]
(4/8)
2009 Post-
validation
Cross-sectional
survey
Light trap (Black Hole) 5,380
mosquitoes
PCR analysis
Sri Lanka (2015) Culex spp. Rao et al. 2014c [36]
(7/8)
Not
stated
Post-MDA Cross-sectional
survey
Gravid traps 69,680
mosquitoes
PCR analysis
Rao et al. 2016 [33]
(7/8)
2013–
2014
Post-MDA Cross-sectional
survey
CDC light trap 28,717
mosquitoes
PCR analysis
Rao et al. 2017c [37]
(8/8)
2011–
2016
Post-MDA Longitudinal
survey
CDC gravid traps 48,301
mosquitoes
PCR analysis
Rao et al. 2018d [38]
(6/8)
2015–
2016
Post-MDA Cross-sectional
survey
CDC gravid traps 7,750
mosquitoes
PCR analysis
Tanzania (2014) Multiple Jones et al. 2018 [29,
39] (4/8)
2015 Post-MDA Cross-sectional
survey
CDC gravid traps and CDC light
traps
1,650
mosquitoes
PCR analysis
Togo (2009) Anopheles
spp.
Dorkenoo et al. 2018B
[52] (7/8)
2015 Post-MDA Cross-sectional Pyrethrum spray catch, Human
landing catch and exit trap
collection
10,872
mosquitoes
PCR analysis
1 According to country or region-level mentioned in papers
https://doi.org/10.1371/journal.pntd.0008289.t004
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Diagnostic tests. Most studies involved PCR analysis of mosquitoes (75.0%) rather than
dissection (25.0%).
Comparison between human and mosquito surveillance results
Table 5 summarises studies which performed both human testing and xenomonitoring in the
same geographical area. Overall, there was great variability in survey methods and results
which limited comparisons. Interpretation is also limited by the fact that there are currently no
recommended species-specific Mosquito Infectivity Rate (MIR) thresholds for LF[8, 53]. A
number of studies reported similar results between human testing and xenomonitoring. For
example, Rao et al 2018 (38) showed ICT rates of 3% and an MIR of 3%, but a similar pattern
was not demonstrated in other Sri Lankan studies. There were also examples where human
testing did not detect significant transmission but xenomonitoring did. For example, the study
by Ramaiah et al. reported a mosquito infection rate of 4.7% of mosquitoes when a community
survey performed concurrently found no evidence of human infection on ICT testing.
Fig 3. Reported prevalence of LF tests according to age range. Some studies reported decade age bands starting on an
even year, e.g. 10–19, rather than 11–20. These data are included in the above table under the adjacent decade age band.
https://doi.org/10.1371/journal.pntd.0008289.g003
Fig 4. Reported prevalence of LF tests according to gender.
https://doi.org/10.1371/journal.pntd.0008289.g004
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Table 5. Comparison of human and mosquito surveillance study results.
Reference (Location) Human survey type (Age
range)
Human sampling results (95% confidence interval)
[Sample size]
Xenomonitoring results (95%
confidence interval)
[Sample size]
Ramzy et al. 2006[18]
(Giza, Egypt)
Community survey (�4
years)
MF = 1.2% (0–2.6%); [n = 1064] MIR = 0.19% (0.08–0.38%)
[n = 4,273]BinaxNOW = 4.8% (2.5–7.1%); [n = 1064]
School survey (7 years) BinaxNOW = 0.4%; [n=n.s.]
Bm14 Ab = 0.2% (0.0–0.5); [n = 896]
School survey (11 years) Bm14 Ab = 1.4% (0.3–2.6%); [n = 415]
Ramzy et al. 2006[18]
(Qalubyia, Egypt)
Community survey (�4
years)
BinaxNOW = 3.1% (1.2–4.9%); [n = 764] MIR = 0% (0.00–0.05%)
[n = 4,258]MF = 1.2% (0–2.6%); [n = 764]
School survey (7 years) BinaxNOW = 0%; [n=n.s.]
Bm14 Ab = 0%; [n = 211]
School survey (11 years) Bm14 Ab = 0%; [n = 131]
Mehta et al. 2018[24]
(Pondicherry, India)
Community survey (�5
years)
MF = 0.69% (n.s.); [n = 290] MIR = 0.04% (n.s.)
ICT = 2.35% (n.s.); [n = 290]
Ramaiah et al. 2013[22] (Muppili,
India)
Community survey (15–45
years)
ICT = 0.4% (n.s.); [n = 226] MIR = 0% (n.s.) [n = 366]
Ramaiah et al. 2013[22] (Thenber,
India)
Community survey (1–7
years)
ICT = 0% (n.s.); [n = 50] MIR = 4.7% (n.s.) [n = 339)
Ramaiah et al. 2013[22] (Alagramam,
India)
Community survey (1–7
years)
ICT = 4.6% (1–7 years); [n = 44] MIR = 2.2% (n.s.) [n = 361]
Community survey (15–45
years)
ICT = 3.2% (15–45 years); [n = 95]
Coulibaly et al. 2016[27] (Sikasso
District, Mali)
Community survey 2009 (6–
7 years)
ICT = 0% (0.00–1.64%); [n = 289] MIR = 0.05% (0.01–0.18%) [n = 4,375]
Community survey 2009
(�8 years)
ICT = 4.9% (3.53–6.67%); [n = 800]
Community survey 2011 (6–
7 years)
ICT = 2.7% (1.24–5.37); [n = 301] MIR = 0% (n.s.) [n = 2,803]
Community survey 2011
(�8 years)
ICT = 3.5% (2.40–5.12%); [n = 795]
Community survey 2012 (6–
7 years)
ICT = 3.9% (2.04–7.00%); [n = 285] MIR = 0% (n.s.) [n = 5,691]
Community survey 2012
(�8 years)
ICT = 2.8% (2.08–3.65%); [n = 1,812]
Coulibaly et al. 2015[26]
(Sikasso District, Mali)
Community survey (�2
years)
MF = 0% (n.s.); [n = 760] MIR = 0.02% (n.s.) [n = 4,680]
ICT = 7.2% (n.s.); [n = 760]
Richards et al. 2011[28] Community survey (�2
years)
MF = 0.9% (n.s.); [1,720] MIR = 0.4% (n.s.) [n = 4,398]
(Plateau/Nasarawa States, Nigeria) ICT = 7.4% (n.s.); [1,720]
Mitja et al. 2018[29] (Papua New
Guinea)
Community survey (10–79
years)
BinaxNOW = 1.1% (0.6–2.0%) MIR = 0%
Rao et al. 2017[37]
(Colombo, Sri Lanka)
School survey (6–8 years) MF = 0% (0–1.0%); [n = 372] MIR = 0.34% (0.2–0.6)
[n = 4,000]ICT = 0% (0–1.0%); [n = 372]
Bm14 Ab = 0% (0–1.0%); [n = 360]
Community survey (�10
years)
MF = 0% (0–0.7%); [n = 506]
ICT = 0% (0–0.7%); [n = 506]
Rao et al. 2017[37]
(Gampaha, Sri Lanka)
School survey (6–8 years) MF = 0% (0–1.0%); [n = 366] MIR = 0.23% (0.1 - 0.4%)
[n = 4,080]ICT = 0.3% (0.5–1.5%); [n = 366]
Bm14 Ab = 0.6% (0.1–2.1); [n = 335]
Community survey (�10
years)
MF = 0% (0–0.7%); [n = 512]
ICT = 0.4% (0.1–1.4%) [n = 512]
(Continued)
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Comparison with TAS results
18 studies reported alternative surveillance methods which were performed concurrently with,
or subsequent to, a TAS which was passed successfully. The comparative results are illustrated
in Table 6 which shows that alternative surveillance methods can identify evidence to support
ongoing transmission in areas which passed TAS. For example, Sheel et al. report LF preva-
lence (using Filarial Test Strips) of 6.2% in a community survey in an area, which had recently
passed TAS[14]. In American Samoa, Lau et al. (2014) found levels of Og4C3Ag to be 3.2%
and Wb123 Ab to be 8.1% in an area which had recently passed TAS. Xenomonitoring surveys
also appear to have utility in identifying hotspots, as in the case of Rao et al. (2018) who
detected a MIR of 5.2% in an area which had recently passed TAS[38].
Integration of surveillance with other disease programmes
The WHO recommend integrating post-MDA surveillance strategies with other ongoing sur-
veillance activities[4]. Only three papers reported on efforts to integrate LF surveillance with
other activities. A study from American Samoa tested stored bloods from a leptospirosis survey
for LF[10]. Two studies from Togo integrated LF testing (using either MF or Og4C3 Ag)
within routine malaria investigations either at the point of the diagnostic test being taken in
the healthcare facility, or when the blood film was being analysed in the laboratory[40, 42].
Table 5. (Continued)
Reference (Location) Human survey type (Age
range)
Human sampling results (95% confidence interval)
[Sample size]
Xenomonitoring results (95%
confidence interval)
[Sample size]
Rao et al. 2017[37]
(Kalutara, Sri Lanka)
School survey (6–8 years) MF = 0% (0–1.0%); [n = 380] MIR = 0.26% (0.1 - 0.4%)
[n = 3,986]ICT = 0% (0–1.0%); [n = 380]
Bm14 Ab = 2.4% (1.3–4.5%); [n = 378]
Community survey (�10
years)
MF = 0% (0–0.7%); [n = 528]
ICT = 0% (0–0.7%); [n = 528]
Rao et al. 2017[37]
(Ambalangoda, Galle, Sri
Lanka)
School survey (6–8 years) MF = 0% (0–1.0%); [n = 379] MIR = 1.17% (0.8–1.6%)
[n = 3,993]ICT = 0.3% (0–1.5%); [n = 379]
Bm14 Ab = 2.3% (1.1–4.4%); [n = 353]
Community survey (�10
years)
MF = 0.2% (0.3–1.0%); [n = 520]
ICT = 1.0% (0.4–2.2%); [n = 520]
Rao et al. 2017[37]
(Unawatuna, Galle, Sri
Lanka)
School survey (6–8 years) MF = 0.3% (0–1.5%); [n = 359] MIR = 1.23% (0.8–1.7%)
[n = 4,002]ICT = 1.1% (0.4–2.8%); [n = 359]
Bm14 Ab = 4.2% (2.5–7.0%); [n = 333]
Community survey (�10
years)
MF = 0.2% (0.0–1.0%); [n = 523]
ICT = 1.5% (0.8–2.9%); [n = 523]
Rao et al. 2017[37]
(Matara, Sri Lanka)
School survey (6–8 years) MF = 0% (0–1.0%); [n = 371] MIR = 1.09% (0.7–1.5%)
[n = 4,080]ICT = 0% (0–1.0%); [n = 371]
Bm14 Ab = 2.2% (1.1–4.2%); [n = 367]
Community survey (�10
years)
MF = 0.2% (0.0–1.0%); [n = 525]
ICT = 0.2% (0–1.0%); [n = 525]
Rao et al. 2014[36]
(Sri Lanka)
Community survey (�10
years)
MF = 0–0.9% MIR = 0–1.56%
ICT = 0–3.4%
Rao et al. 2018[38] (Sri Lanka) Community survey (10–70
years)
MF = 1.1% (0.5–2.5%) MIR (2015) = 5.2% (4.2–6.3%)
ICT = 3.0% (1.8–4.9%) MIR (2016) = 3.0% (2.3–3.8%)
Rao et al. 2016[33] (Sri Lanka) Community survey (2–70
years)
MF = 0% (0.02–0.09%) MIR = 0.36% (0.29%-0.45%)
https://doi.org/10.1371/journal.pntd.0008289.t005
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Table 6. Results of alternative surveillance conducted in settings which underwent concurrent TAS.
Country Reference Date passed
TAS
Study
date
Study type Age Sample size Results (95% C.I.s if stated)
American
Samoa
Lau et al. 2014 [11] 2011 2010 Community survey �18
years
807 participants Og4cC3 Ag>32 units = 3.2% (0.6–
4.7%);
Wb123 Ab = 8.1% (6.3–10.2%)
Bm14 Ab = 17.9% (15.3–20.7%)
Schmaedick et al. 2014
[44]
2011 2011 Xenomonitoring
survey
N/A 15,215 mosquitoes MIR rate = 0.28% (95% CI 0.20–0.39)
Sheel et al. 2018 [14] 2015 2016 Community survey �8 years 2,507 participants FTS = 6.2% (4.5–8.6%)
MF = 22/86 +ve
Won et al. 2018 [13] 2011 2011 Enhanced TAS1 5–10
years
1,134 participants BinaxNOW = 0.2%
Wb123 Ab = 1.0%
Bm14 Ab = 6.8%
Bm33 Ab = 12.0%
2015 2015 Enhanced TAS1 5–10
years
864 participants BinaxNOW = 0.1%
Wb123 Ab = 3.6%
Bm14 Ab = 3.0%
Bm33 Ab = 7.8%
Bangladesh Irish et al. 2018 [45] 2015 2016 Xenomonitoring
survey
N/A 5,926 mosquitoes MIR = 0%
Egypt Moustafa 2014 [17] 2012 2012 Community survey �18
years
1,321 participants BinaxNOW = 0%
Bm14 Ab = 2.2%
Madagascar Garchitorena et al.
2018 [25]
2016 2016 Community survey �5 years 545 participants FTS = 15.78% (12.88–19.18%)
Sri Lanka Rao et al. 2014a [36] 2012–13 2012–13 Community survey �10
years
7,156 participants MF = 0–0.9%
BinaxNOW = 0–3.4%
Rao et al. 2014b [36] 2012–13 2012–13 Enhanced TAS1 6–7 years 17,000 participants Bm14 Ab = 0–6.9% across school sites
Rao et al. 2014c [36] 2012–13 2012–13 Xenomonitoring
survey
N/A 69,680 mosquitoes
sampled
MIR = 0% - 1.56%.
Rao et al. 2016 [33] 2012–13 2014 Xenomonitoring
survey
N/A 28,717 mosquitoes MIR = 0.36% (0.29–0.45%).
Rao et al. 2017c [37] 2013 2015–17 Community survey �10
years
3,123 participants (6
sites)
BinaxNOW = 0–1.5%
MF = 0–0.2% (n.s.)
Rao et al. 2017c [37] 2013 2015–17 School survey 6–8 years 2,227 participants (6
sites)
BinaxNOW = 0.0–1.1%
MF = 0–0.3%
Bm14 Ab = 0–4.2%
Rao et al. 2017c [37] 2013 2015–16 Xenomonitoring
survey
N/A 24,061 mosquitoes (6
sites)
MIR = 0.23% (Peliyagoda) - 1.23%
(Unawatuna)
Rao et al. 2018d [38] 2013 2015–16 Xenomonitoring
survey
N/A 2015: 4,000
mosquitoes
2015: MIR = 5.2% (4.2–6.3%).
2016: 3,750
mosquitoes
2016: MIR = 3.0% (2.3–3.8%).
Rao et al. 2018a [38] 2013 2015 School survey 6–7 years 401 participants BinaxNOW = 1.2% (0.5–2.8%)
MF = 0.2% (0.0–1.4%)
Bm14 Ab = 5.7% (3.7–8.4%)
Rao et al. 2018b [38] 2013 2015 Community survey 10–70
years
528 participants BinaxNOW = 3.0% (1.8–4.9%)
MF = 1.1% (0.5–2.5%)
Rao et al. 2018c [38] 2013 2015 Community survey �2 years 16,927 participants MF = 0.6% (0.47–0.71%)
(Continued)
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Discussion
This review provides a timely collation of important information on alternative surveillance
strategies for low prevalence and/or post-validation settings that will be useful to national pro-
grammes over the next decade as they seek to reduce LF incidence and meet the challenges of
the NTD Roadmap 2030 [54]. However, the significant heterogeneity found in the study
designs, population sampled, use of diagnostic tests and reporting metrics, highlights the need
for more systematic methods and new WHO guidelines to be developed to supplement TAS.
This review has identified that the sensitivity of LF surveillance in selected low prevalence
populations can be increased by changes to the diagnostic test and/or study population. TAS is
an important programmatic tool to guide decisions on when to stop MDA but several studies
report that it lacks sensitivity when used in low prevalence settings, such as a post-validation
context[13, 17, 23, 38], and may not accurately describe the spatial distribution of LF at com-
munity-level[14]. This is important because evidence from countries that have recently elimi-
nated LF indicates an increased risk of disease recrudescence, with ongoing hotspots of
infection documented recently in both American Samoa and Sri Lanka[5, 12, 38]. The lag time
between infection with LF and onset of symptoms may be 10 years or more, demonstrating the
critical importance of maintaining surveillance programmes following elimination[41, 51]
Alternative diagnostic tests
The studies included in this review indicate that there may be benefit in moving from the con-
ventional rapid antigen tests to antibody tests as they increase the proportion of positive results
and, hence, the likelihood that residual hotspots will be detected. However, antibody tests are a
measure of the host response to infection which can persist for some time after all antigenic
material from the original infection has been eliminated. This means that antibody tests are
associated with an increased false-positive rate and the detection of more historical cases,
meaning there would be financial and logistical implications to switching to widespread anti-
body testing[13].
Antibody tests could be added to TAS without significant changes to study design[13].
Reported results suggest that testing Wb123 antibody (Ab) may have particular utility since it
is thought to both become positive relatively soon after infection and decay faster following
clearance, compared to Bm14 Ab[27, 55]. It also has been found to be significantly associated
with molecular xenomonitoring results, suggesting it could act as an indicator of ongoing
transmission[13, 55]. Urine ELISA may have greater acceptability than blood testing but
requires further validation in LF-endemic regions[16, 35]. However, the current increased
costs of antibody and ELISA tests may limit their widespread uptake and further research is
needed to characterise the spatial distribution of antibody signals[13].
All methods of human surveillance are affected by the persistence of the marker (antibody
or antigen) in circulation. This is of variable duration for different test types, meaning that
their results are not directly comparable. It also means that results are not truly indicative of
Table 6. (Continued)
Country Reference Date passed
TAS
Study
date
Study type Age Sample size Results (95% C.I.s if stated)
Togo Dorkenoo et al. 2018B
[52]
2015 2015 Xenomonitoring
survey
N/A 10,872 mosquitoes MIR = 0%.
1 Standard TAS with the addition of antibody testing
https://doi.org/10.1371/journal.pntd.0008289.t006
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current infectivity and will therefore include cases of historical disease. By contrast, mosquito
surveillance gives a snapshot indication of current infection, and could serve as a useful
adjunct to human surveillance methods[27, 47]. However, mosquito surveillance requires
entomology and laboratory capacity, which are both costly and time-consuming, meaning that
it is typically only used in very defined areas, rather than for population-wide surveillance[27,
45].
Alternative approaches to sampling
Studies reported that LF tests typically report higher prevalence of infection in adults than in
children[14, 31] and it is thought that adults (particularly adult men) may represent the major-
ity of the reservoir of infection for LF[37]. As prevalence reduces it may therefore also be
appropriate to target surveillance to focus on these high-risk populations. Methods that have
been suggested include adopting a ‘test and treat’ approach for adult males, which could focus
on settings in which they may be more likely to congregate, such as marketplaces[37].
Post-validation surveillance in Togo found positive cases in low-risk areas, highlighting the
importance of developing surveillance systems with nationwide coverage[40, 42]. Areas with
high levels of migration from endemic countries (e.g. border areas) may also require additional
monitoring[24, 56]. Other recommended sampling methods include community-based meth-
ods targeting adults and children, school-based surveys with a wider age range and snowball
sampling of positive cases[14].
Future research needs
In order to support countries to develop appropriate surveillance in low prevalence or post-
validation settings, further research will be required to inform choices regarding the selection
of diagnostic tests and appropriate sampling strategies. This will include work to determine
the diagnostic performance and cost-effectiveness of novel tests in a range of different epide-
miological settings and the identification of suitable threshold values for new LF diagnostic
tests in humans[13]. Further research is also required to determine appropriate sample size
and infection cut-off thresholds for surveillance in different mosquito species[18, 26, 44, 52].
There is a need to better understand the spatial and temporal dynamics of LF hotspots and
their drivers, which will require more longitudinal studies to help inform future control and
surveillance activities[12, 23]. Emerging evidence suggests that LF hotspots may be highly
focal, increasing the likelihood that cluster-based methods will lack sensitivity to detect them
[10, 12, 23, 57]. The risk of recrudescence of infection will depend on a range of factors includ-
ing population density, baseline endemicity, uptake of MDA and concurrent vector control
interventions. It may be appropriate to stratify the intensity of population-level surveillance
based on assessment of these factors[58]. This must be supported by the development of data
systems capable of continuously collecting, analysing and interpreting data in order to rapidly
inform service planning and policy[6].
Further, there is a particular need to increase the evidence base in the African and South
Asian Regions, which currently have the majority of ongoing transmission[1]. The evidence
base supporting integration of surveillance activities with other health system processes must
also be strengthened. Examples may include blood donation systems, surveillance for other
co-endemic NTDs (e.g. onchocerciasis) or malaria and routine household surveys[24, 40, 41,
48]. Finally, post-validation surveillance programmes will require clear guidance on how to
respond to the identification of new cases. Such interventions may include watchful waiting,
vector control, resumption of MDA, treatment of cases only, or a combination of methods
[36].
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Limitations
It was not possible to conduct a meta-analysis of surveillance results which was largely due to
the variation in study methods, but also because of the variation in the infectivity of different
mosquito vectors and the influence of different environmental factors that are difficult to con-
trol for.
Regarding the study exclusion criteria, the decision to limit the analysis to the English lan-
guage led to the exclusion of a small number of papers published in Spanish or Chinese, but
we consider it unlikely that these results would have significantly changed the main outcomes
of this review. The decision to limit the review to papers published after 2000 also excluded a
small number of papers but it was considered that the results of more historical studies were
likely to have limited transferability to current LF programmes. Finally, our search for unpub-
lished data was limited. It is likely that some studies examining surveillance methods are con-
ducted as part of routine LF programmatic activities and, hence, not published. If collected,
such data could strengthen the evidence base in this area.
Conclusions
This is the first review to systematically investigate the evidence supporting alternative (non-
TAS) approaches to LF surveillance in low prevalence and post-validation settings. The results
demonstrate a need for a more standardised approach to LF surveillance in low prevalence
and post-validation settings. Surveillance methods with greater sensitivity and more targeted
sampling strategies to better detect residual hotspots than the current TAS methodology will
be required. However, further research on the diagnostic performance and cost-effectiveness
of new diagnostic tests, and how these can be integrated within routine health system activity,
is needed to inform policy decisions over the next decade.
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